Hair regrowth treatments for cis-males include Minoxidil, Finasteride, and RU58841. Estrogen and testosterone blockers can help restore hair loss but may not suit everyone.
A user's success in treating their hair loss with 2x daily topical dutasteride and minoxidil, as well as the potential for using less frequent application of topical dutasteride due to its long half-life.
The potential effectiveness of homemade topical spironolactone in treating hair loss, with studies suggesting it is more effective than finasteride and even minoxidil when used as monotherapy. The conversation also mentions that other anti-androgens are being developed which may soon hit the market.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
RU58841, oral and topical minoxidil, finasteride, and ketoconazole shampoo led to significant hair regrowth, though some suspect a hair transplant. Concerns about RU58841's side effects, like anxiety and heart issues, were discussed.
The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Hair loss treatments discussed include Minoxidil, Finasteride, RU58841, and Dutasteride injections. Users believe these treatments are effective and help maintain good hair.
New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.
The user experienced severe side effects with topical finasteride, continued using Minoxidil, and was advised to try topical dutasteride after a test suggested they might not respond to finasteride. They are hesitant to start the new treatment due to past side effects.
The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
Hair loss treatments, specifically Minoxidil and the tap method; Finasteride was also discussed but not recommended due to its side effects. Price and other information were requested.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation humorously speculates on whether an elderly man's good hairline is due to finasteride, dutasteride, or genetics. It also discusses the role of DHT and genetics in hair loss.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
A user is considering microneedling to enhance absorption of a prescribed topical hair loss treatment containing Minoxidil, Dutasteride, and Latanoprost, while already taking oral Minoxidil and Dutasteride. They seek advice on the effectiveness and safety of combining these treatments, especially due to the cost and their desire to maximize results.
Hair loss discussion includes Amplifica, a new treatment by Dr. Rassman and Dr. Plikus using molecules from hairy moles. No progress updates mentioned.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
A user applied pyrilutamide for 6 months without hair regrowth and is considering stopping due to cost and lack of results. Another user suggests switching to finasteride, which is cheaper and has shown regrowth for them.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. L'Oreal's study on Stemoxydine 5% claims a 4% increase in hair density after 3 months, but some users question potential bias.
Actifollic selling Pyrilutamide as a treatment for hair loss, with people debating its efficacy compared to Minoxidil and Finasteride in combination with RU58841.
Potential treatments for hair loss, specifically the combination of liquid minoxidil and pyrilutamide, with some suggesting that adding finasteride may be beneficial.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
The conversation is about using valproic acid, an anti-seizure medication, as a topical treatment to promote hair growth. The original poster is seeking personal experiences from those who have tried this method.
There is no consensus on how long to wait after dermarolling before applying Minoxidil, with some applying immediately and others waiting up to 24 hours. Users report varying experiences with side effects, and some also use finasteride or dutasteride in their hair loss treatment routines.
A new therapy aimed at destroying DHT receptors in the scalp is still in early trials and may take at least 5 years to become available. A sugar-like solution similar to Minoxidil is also in early testing stages and not yet commercialized.